Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS
NCT ID: NCT01245803
Last Updated: 2010-11-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
400 participants
INTERVENTIONAL
2010-04-30
2011-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rosuvastatin,one month,lipid lowering
additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI
additional rosuvastatin loading
additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
sugar pill, one month
sugar pill is given 18-24hr and 4-6hr before PCI as control
placebo control
sugar pill is given 18-24hr and 4-6hr before PCI as control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
additional rosuvastatin loading
additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
placebo control
sugar pill is given 18-24hr and 4-6hr before PCI as control
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosed as acute coronary syndrome
* Plan to PCI
Exclusion Criteria
* emergency PCI(\<2h) for NSTE-ACS
* History of liver disease and myopathy (ALT/AST\>3 x upper limit of normal,CK\>5 x upper limit of normal)
* TG\>500mg/dl,CCr\<30ml/min
* inflammatory disease
* allergic to rosuvastatin
* nephrotic syndrome,hypothyroidism,systemic lupus erythematosus,myeloma,et.al.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Anzhen Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
BeijingAnzhen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the 28th division, Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6998
Identifier Type: -
Identifier Source: org_study_id